Jefferies Financial Group began coverage on shares of Lantheus (NASDAQ:LNTH) in a report released on Monday, The Fly reports. The brokerage set a “buy” rating and a $29.00 price target on the medical equipment provider’s stock. Jefferies Financial Group’s price target indicates a potential upside of 107.00% from the company’s previous close.
LNTH has been the subject of several other research reports. CJS Securities raised Lantheus from a “market perform” rating to an “outperform” rating in a report on Tuesday, June 16th. BidaskClub raised Lantheus from a “sell” rating to a “hold” rating in a research note on Tuesday, June 23rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $29.00.
NASDAQ:LNTH opened at $14.01 on Monday. The stock has a 50-day simple moving average of $13.48 and a two-hundred day simple moving average of $15.28. Lantheus has a 52-week low of $8.67 and a 52-week high of $29.80. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.41 and a current ratio of 2.91. The firm has a market capitalization of $529.55 million, a PE ratio of 22.60 and a beta of 1.26.
Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.07. Lantheus had a return on equity of 46.94% and a net margin of 7.13%. The business had revenue of $90.70 million during the quarter, compared to analyst estimates of $91.70 million. During the same quarter in the previous year, the company posted $0.28 earnings per share. Lantheus’s revenue for the quarter was up 4.9% on a year-over-year basis.
In related news, SVP Michael P. Duffy sold 7,198 shares of the business’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $13.13, for a total value of $94,509.74. Following the sale, the senior vice president now directly owns 133,402 shares in the company, valued at $1,751,568.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Mary Anne Heino sold 30,033 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $13.77, for a total value of $413,554.41. Following the completion of the sale, the chief executive officer now owns 634,318 shares in the company, valued at $8,734,558.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,653 shares of company stock valued at $542,675. Corporate insiders own 2.08% of the company’s stock.
Several large investors have recently bought and sold shares of LNTH. Victory Capital Management Inc. lifted its position in shares of Lantheus by 21.9% in the fourth quarter. Victory Capital Management Inc. now owns 26,334 shares of the medical equipment provider’s stock worth $461,000 after buying an additional 4,726 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Lantheus by 5.7% in the fourth quarter. Rhumbline Advisers now owns 121,601 shares of the medical equipment provider’s stock worth $2,494,000 after buying an additional 6,598 shares in the last quarter. Swiss National Bank lifted its position in shares of Lantheus by 2.2% in the fourth quarter. Swiss National Bank now owns 74,300 shares of the medical equipment provider’s stock worth $1,524,000 after buying an additional 1,600 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Lantheus by 392.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,223 shares of the medical equipment provider’s stock valued at $188,000 after purchasing an additional 7,350 shares during the period. Finally, Bank of Montreal Can raised its position in Lantheus by 50.4% during the fourth quarter. Bank of Montreal Can now owns 342,263 shares of the medical equipment provider’s stock valued at $7,020,000 after purchasing an additional 114,762 shares during the period. Institutional investors own 98.00% of the company’s stock.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Read More: Cost of Debt
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.